Phase 2 N=14 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
Neuromyelitis Optica · Devic's Disease
Primary: Median Number of Neuromyelitis Optica (NMO) Attacks Per Year — 3; 0 attacks per year — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=16 Neuromyelitis Optica (NMO) & Cetirizine
Neuromyelitis Optica
Primary: Annualized Relapse Rate Before Cetirizine — 0.4; 0.1 relapses per year
Phase 3 N=231 N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Primary: Time to Adjudication Committee (AC)-Determined Neuromyelitis Optica Spectrum Disorder (NMOSD) Attack During RCP — NA; NA Days — p=<0.0001
Phase 1 N=6 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
Neuromyelitis Optica · Neuromyelitis Optica Spectrum Disorder
Primary: Change in Neurological Disability - Expanded Disability Scale Score — 4.0; 6.5; 6.5; 4.0 EDSS unit score
Phase 1 N=10 C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation
Neuromyelitis Optica
Primary: Number of Adverse Safety Events During Hospitalization — 0 adverse safety events
Phase 3 N=166 A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Neuromyelitis Optica Spectrum Disorder
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 162; 44 Participants
Phase 3 N=86 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients
Neuromyelitis Optica Spectrum Disorder
Primary: Annual Relapse Rate — 1; 1.30; 0.51; 0.21 Number of relapses
Phase 1 N=10 Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
Neuromyelitis Optica · Neuromyelitis Optica Spectrum Disorder
Primary: Baseline Expanded Disability Status Score (EDSS) — 3.5 units on a scale
Phase 3 N=84 Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
Neuromyelitis Optica (NMO) · NMO Spectrum Disorder (NMOSD)
Primary: Time to First Protocol-Defined Relapse (TFR) in the Double-Blind Period — 120.6; NA weeks — p=0.0184
Phase 3 N=119 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
Neuromyelitis Optica · Neuromyelitis Optica Spectrum Disorder
Primary: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events — 41; 70; 14; 26 Participants
Phase 3 N=95 Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Neuromyelitis Optica (NMO) · NMO Spectrum Disorder (NMOSD)
Primary: Time to First Protocol-Defined Relapse (TFR) During the Double-Blind (DB) Period — 128.3; NA weeks — p=0.0184
Phase 3 N=46 Ampyra for Optic Neuritis in Multiple Sclerosis
Multiple Sclerosis · Optic Neuritis
Primary: Efficacy of Dalfampridine on Visual Function by Early Diabetic Treatment Retinopathy Study (EDTRS) 5% Contrast Sensitivity Scores — -0.04; -0.06; -0.08; -0.06 LogMAR…
Phase 3 N=105 An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
Neuromyelitis Optica · Neuromyelitis Optica Spectrum Disorder
Primary: Number of Participants With an Adjudicated On-trial Relapse in the Primary Treatment Period — 0; 20 Participants — p=< 0.0001
Phase 2 N=82 BIIB033 In Acute Optic Neuritis (AON)
Acute Optic Neuritis
Primary: Change in Full-field Visual Evoked Potential (FF-VEP) Latency at Week 24: Intent-to-treat (ITT) Population — 20.83; 17.34 msec — p=0.3337
N/A N=23 Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
Multiple Sclerosis
Primary: Change in the Number of Enhancing Leptomeningeal Foci on 1 Year Follow up Compared to Baseline in MS Patients Treated With Ocrelizumab. — 0.07 number of enhancing foci
Phase 2 N=73 POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler
Relapsing-remitting Multiple Sclerosis · RRMS
Primary: Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment — 2.4; 3.2; 3.9; 5.4…
Phase 2 N=46 High Frequency Impulse Therapy for Neuropathic Pain in NMOSD
Neuromyelitis Optica
Primary: Change in Pain Score on the Numerical Rating Score (NRS) — 2.2; 1.3 units on a scale
Phase 1 N=2 Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy
Nonarteritic Anterior Ischemic Optic Neuropathy
Primary: Change in Visual Acuity — 4; 3 lines change in Snellen chart
Phase 2 N=71 Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis
Optic Neuritis
Primary: Retinal Ganglion Cell Inner Plexiform Layer Thickness — 36.56; 34.65; 31; 29.42 micron
Phase 3 N=44 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)
Optic Neuritis
Primary: Retinal Nerve Fiber Layer Thickness at Baseline and Month 6 — 128.1; 130.5; 89.5; 88.0 µm
Phase 4 N=30 Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis
Multiple Sclerosis
Primary: Relapses Post Partum — 2; 7 Participants
N/A N=22 Scrambler Trial for Pain in NMOSD
Neuromyelitis Optica
Primary: Acceptability as Assessed by the Number of Participants Responding Yes to a Question — 7; 5 Participants
Phase 4 N=19 Natalizumab De-escalation With Interferon Beta-1b
Relapsing-remitting Multiple Sclerosis
Primary: Number of Days Until First On-study Relapse — NA; 103 days — p=0.125
N/A N=40 Citicoline in Non-Arteritic Ischemic Optic Neuropathy
Non-arteritic Ischemic Optic Neuropathy
Primary: Change From Baseline in Visual Acuity at 9 Month — -0.0574; 0.0535 LogMAR
Phase 2 N=52 Long-Term Assessment of Remyelinating Therapy
Acute Optic Neuritis
Primary: FF-VEP Latency of the Affected Eye as Compared to the Baseline of the Fellow Eye at 2 Years (+ up to 12 Months) After the Last Study Visit Assessment (Week 32) in RENEW…
Phase 2 N=19 Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis
Multiple Sclerosis · Internuclear Ophthalmoplegia · Fatigue
Primary: Pulse Size Ratio (PSR): Abducting/Adducting Eye Ratio for Saccadic Peak Velocity. — 1.914; 1.937; 1.805; 1.898 ratio — p=0.842672
Phase 2 N=32 Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
Multiple Sclerosis
Primary: Percentages of Patients With Treatment-emergent Adverse Events (TEAEs) or Treatment-emergent Serious Adverse Events (TESAEs) — 100; 100; 88.9; 100 percentage of…
Phase 2 N=9 Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins
Multiple System Atrophy
Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events
Phase 2 N=15 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
Chronic Inflammatory Demyelinating Polyneuropathy · Peripheral Neuropathy · Charcot-Marie-Tooth Disease
Primary: Motor Nerve Conduction Velocity (m/Sec) — 1.67 m/s — p=0.7615
Phase 2 N=54 Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis
Multiple Sclerosis
Primary: Expanded Disability Status Scale (EDSS) Plus — 17; 17 Participants — p=1.0